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INTRODUCTION 
Sickle cell disease (SCD) is a hereditary disease caused 
by substitution of the amino acid valine instead of 
glutamic amino acid in the sixth position of the beta chain 
and sickle hemoglobin production is caused. Sickle 
hemoglobin in the time of lack of oxygen, has less 
soluble than normal hemoglobin A and by forming a rod-
like bodies within the red blood cells provide their 
destruction. Sickle gene of red blood cells, a common 
mutation in the areas of malaria which protect them 
against cerebral malaria Falysparm diseases.
1-3
 
History of the sickle gene along with the recognition and 
the incidence of malaria. Nuclear and mitochondrial 
DNA analysis shows populations living in Africa have 
this mutation 50000 years ago. SCD include all cases of 
Hbs homozygous and all cases of compound 
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Background: Red blood cell (RBC) transfusions are frequently used in patients with sickle cell disease (SCD) to treat 
and prevent of their disease complications. However repeated blood transfusions are often complicated by RBC 
alloimmunization. Race and antigenic pattern differences are the common risk factor to develop alloimmunization. 
This study was performed to determine the frequency of RBC alloimmunzation in sickle cell patients and healthy 
blood donors.  
Methods: This is a cross sectional study that has been done on 140 patients with SCD and 140 healthy blood donors 
from April 2015 to April 2016. The RBC phenotype of all patients and donors investigated by Tub method and all 
panel test phases were done at immunohematology laboratory of Iranian Blood Transfusion Organization of Ahwaz.  
Results: Of all SCD patients 61 (43.6%) were male and 79 (56.4%) were female. 68 (48.5%) were HbSS and 72 
(51.4%) were S/B thalassemia. The mean age of patients was 19.69 (range: 2-60) years. Of all patients, 114 (81.25%) 
had received transfusion. The RBC alloimmunization rate among SCD patients was 7.1% and 50% of the RBC 
alloimmunization had anti-Kell and 30% had anti-Rh. The comparison of the RBC phenotypes between the group of 
patients with SCD and the group of blood donors (non-Arab) revealed a statistically significant difference in the 
frequency of S (54% vs. 67%, p=0.024), M (82.7% vs. 90.7%, p=0.049), and FYb (73.4% vs. 55.7%, p=0.002).  
Conclusions: Althoguh alloimmunization rate in SCD patients in this study was lower than reported by other studies 
but cross matchining at least for the Rh and Kell systems from the time of initial transfusion may decrease the 
incidence of alloimmunization.  
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heterozygote mutation that one gene get mutation sickle 
and another gene get other mutations include Hbs, 
thalassemia, HbD, Hbo Arab. In SCD hemoglobin 
homozygous not produce and RBC include 90-100% of S 
hemoglobin. In compand homozygous, Hbs was more 
than HbA and in sickle form, RBC 20-40% of Hbs.
1-3
 
Iran sickle cell with higher f hemoglobin more similar to 
Suadia and Indian-Asian type.
4
 
The severity of signs in the SCD is more different and 
some of them without sign and recognized only in 
screening programs and some others suffered to pain. 
Complications of SCD including sickle cell dactylitis, 
sepsis, acute chest syndrome, pulmonary hypertension, 
kidney disease. Some patients to prevent attacks, strokes, 
cardiovascular failure, hematuria long-term, repeated 
Pysm fairies require repeated and chronic blood 
injections.
1-3
 
Some of patients need for repeated blood injection has 
Immune response against the antigen in RBC which this 
phenomenon called Alloimmunization.
1-6
 
The rate of alloimmunization in some areas reported 7-
20% and in North American 8-50%.
1,5,7
 
Age, sex, number of transfusions, unknown racial and 
genetic factors differences between recipients and blood 
donors are involved in the creation of alloimmunization.
1-
3,5
 
Given that SCD after thalassemia is the second common 
hemoglobinopathy and also racial and phenotype 
differences among SCD patients and blood donors as one 
of the effective and important causes in the development 
of alloimmunization, the aim of this study was to 
determine the frequency of alloimmunization in patients 
with SCD and blood donors. 
METHODS 
This cross-sectional study has been done on 140 patients 
with SCD and 140 randomly selected blood donors from 
April 2015 to April 2016. At admission time, a 
questionnaire included questions about time of last blood 
donor; IVIG and antibiotic receiving were asked patients. 
Patients with transfusion less than one month and getting 
IVIG not included in the study. Blood samples from SCD 
patients and donors were phenotyped, using standard 
techniques recommended for the following red-cell 
antigens: A, B, C, D, E, C, E, K, k, M, N, s, S, FYa, FYa, 
JKb and JKa. Consent form completed for all patients and 
patients didn’t pay any money for their experiments. 
Collected data analyzed by statistical methods in 
SPSS.16. 
RESULTS 
In this study 140 patients with SCD were studied. 61 
(43.5%) of them were male and 72 (51.5%) were 
thalassemia sickle cell which of them, 45 (32%) cases 
were positive beta sickle and 27 (19.2%) zero thalassemia 
sickle. The mean age of patients was 16.7 (range 2-60). 
The mean of hemoglobin was 8.2 (range 6-13). 31 (22%) 
of patients have splenomegaly and 23 (16.4%) have 
splenectomy. Most of patients with history of exchange 
transfusion have severe pain attack (72.2%) (Table 1). 
Table 1: Characteristics of the study participants with 
SCD. 
Variables  n % 
Sex   
61 
 
43.5 Male 
Female 79 56.5 
Type of sickle cell  
68 
 
48.5 Homozygous 
Thalassemia  72 51.5 
History of blood 
transfusion (yes) 
114 81.3 
Start age of bloodletting in 
transfused patients 
 
 
47 
 
 
41.2 <3 
>3 67 58.8 
History of exchange 
transfusion (yes) 
18 12.8 
Table 2: Comparison between frequency of RBC in 
SCD patients and healthy Arabian donors. 
P value SCD (%) 
 Arabian 
donors (%) 
RBC 
antigen 
70.0 9/97  9/92  e 
9/0  7/80  80 c 
3/0  40 9/32  E 
41/0  3/79  3/74  C 
31/0  95 4/91  D 
016/0  1/67  50 S 
6/0  65 4/61  N 
015/0  7/90  6/78  M 
79/0  4/6  0 K 
035/0  5/88  1/77  s 
006/0  7/55  4/75  F.y.b 
26/0  7/55  8/63  F.y.a 
88/0  6/68  6/69  J.k.b 
95/0  9/72  5/72  J.k.a 
The RBC alloimmunization rate among SCD patients was 
7.1% which 70% of them were female and rest of them 
were males. Of alloimmunization cases 90% have 
bloodletting age more than three years and the incidence 
of alloimmunization increased significantly by increasing 
the first age of blood transfusion. In this study there 
wasn’t significant relation between alloimmunization and 
rate of injection volume. The frequency of allo-antibody 
orderly were 50% anti-Kell, 30% anti-E and 10% anti-D 
and 10% unknown, respectively. The frequency of minor 
blood groups in two groups were in phenotype S (50% in 
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healthy Arabian donors vs. 67.1% in sickle cell patients, 
p=0.016), phenotype M (78.6% in healthy Arabian 
donors vs. 90.7%, p=0.01), phenotype s (77.1% in 
healthy Arabian donnor and 88.5% sickle cell patients, 
p=0.035) and FYb (75.4% in healthy Arabian donors vs. 
55.7% in sickle cell patients) and the difference between 
two groups were significant (Table 2). 
Table 3. Comparison between frequency of RBC in 
SCD patients and healthy non-Arabian donors. 
P value 
SCD 
(%) 
Non-arabian 
donors (%) 
RBC 
antigen 
74/0  9/97  1/97  e 
05/0  7/80  6/68  c 
69/0  40 9/42  E 
9/0  3/79  80 C 
47/0  95 1/97  D 
15/0  1/67  1/57  S 
19/0  65 7/55  N 
42/0  7/90  1/87  M 
05/0  4/6  1/21  K 
4/0  5/88  3/84  s 
028/0  7/55  4/71  F.y.b 
07/0  7/55  6/68  F.y.a 
06/0  6/68  7/55  J.k.b 
25/0  9/72  80 J.k.a 
The significant difference only was seen in phenotype 
FYb between blood groups in two groups (55.7% in 
sickle cell patients vs. 71.4% in non-Arabian healthy 
donors, p=0.028) (Table 3). 
Table 4: Comparison between frequency of RBC in 
SCD patients and healthy Arabian/ non-Arabian 
donors. 
P value SCD (%) Donors (%) RBC antigen 
19/0  9/97  95 e 
23/0  7/80  8/74  c 
74/0  40 1/38  E 
64/0  3/79  77 C 
78/0  95 2/94  D 
024/0  1/67  54 S 
24/0  65 3/58  N 
049/0  7/90  7/82  M 
06/0  4/6  20 K 
07/0  5/88  6/80  s 
002/0  7/55  4/73  F.y.b 
07/0  7/55  2/66  F.y.a 
29/0  6/68  6/62  J.k.b 
51/0  9/72  3/76  J.k.a 
There was significant difference in four blood types 
between SCD patients and Healthy Arabian and Non-
Arabian donors that included S(54% in healthy donors vs. 
67% in sickle cell patients, p=0.024), M (82.7% in 
healthy donors vs. 90.7% in sickle cell patients, p=0.049) 
and FYb (73.4% in healthy donors vs. 55.7% sickle cell 
patients, p=0.002) (Table 4). 
DISCUSSION 
The frequency of RBC alloimmunization rate in this 
study was 7.1% and in other studies this rate in SCD 
patients reported in range 4-40%. Several studies have 
indicated that the prevalence of RBC alloimmunization in 
SCD patients is in ranged from 9.9-30% which higher 
than our study results.
11-16 
In a study on major thalassemia patients, this rate 
reported 18.75% which was higher than our study 
report.
15
 
In Gilberto Moreira et al study, the rate of RBC allo-
immunization rate was 12.9% and 80% of alloantibodies 
against Kell and Rh phenotypes. Elliott and et al showed 
that 67% of Alloantibodies against Kell, E, C and 
JKb.
10,12
 
Given the inherently high immunogenicity of blood 
groups Kell and Rh, the prevalence of alloantibody in our 
study and other studies were similar. In this study there 
wasn’t significant difference between alloimmunization 
and the amount of transfused blood based cc/kg/year. In 
sickle cell patients at Brazil, there wasn’t any significant 
difference between alloimmunization frequency and the 
volume of transfused blood.
12
 
The transfused blood age was effective in allo-
immunization incidence rate so that the frequency of allo-
immunization in infants with first transfused blood less 
than three years significantly lower than other infants 
(20.9% vs. 47.5%, p=0.03). 
14
 
In this study, the frequency of RBC alloimmunization has 
relation with age of blood transfusion. Even though, of 10 
patients with RBC alloimmunization, 7 patients were 
female but the difference wasn’t significant and this 
result in line with other studies.
13
 
There was significant in compare phenotype of RBC in 
SCD patients with non-Arabian healthy donoors in monor 
blood groups type FYb (71.4% in non-Arabian healthy 
donors vs. 55.7% in SCD patients, p=0.028) but there 
wasn’t any significant between other phenotypes. FYb 
and FYa are the common Alleles in Asian and Europian 
races and anti FYa and anti FYb found in transfusion 
reactions. Anti FYa cause mild hemolytic anemia but 
FYb didn’t.1 
There was significant difference between healthy donors 
and SCD patients at three phenotypes FYb, M and S. 
Although in our study there wasn’t found any effective 
allo-antibody on FYb, M and S but a significant 
difference in the frequency of minor blood groups will 
predispose alloimmunization in repeated transfusions and 
sometimes inevitable in SCD patients. Alloantibodies M, 
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N and S usually not associated with clinical signs and in 
cases without history of transfusion can be positive. 
1
  
In a study in Brazil only the group type C has significant 
difference between healthy donors and SCD patioents.
12
 
This study showed that racial differences in SCD patients 
is one of the causes of the SCD in patients.
1,12-13
 
In compare minor blood groups between SCD patients 
(commonly are from Arabian races) and healthy non-
Arabian donors, the difference was only seen in FYb 
phenotype but in whiten healthy and sickle cell Arabian 
races the difference between three blood groups was 
significant that could be related due to racial diversity 
among Iranians Arabs (from Sudan, Iraq, Yaman, 
Behraine). In other words, inter-ethnic blood transfusions 
in this study can be associated with the higher risk of 
alloimmunization in patients. 
CONCLUSION  
Patients with SCD, for many reasons such as severe pain, 
acute chest syndrome and stroke are needed regular blood 
transfusions and alloimmunization is one of the 
dangerous side effects of transfusion. Although in this 
study, the phenotype of blood groups of non-Arabian 
healthy volunteers and SCD patients except FYb weren’t 
difference but in compare the phenotype of patients with 
blood donors at least in three phenotypes S, M and FYb 
was significant difference. So it is recommended that a 
database containing comprehensive information about 
phenotype of blood groups of healthy volunteers of both 
race and SCD patients is essential but its formation 
seperatly between SCD patients and Arabian donors not 
necessary. 
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